Literature DB >> 23100180

Cross-sectional survey of the prevalence of reduced estimated glomerular filtration rate, albuminuria and cardiovascular risk in a native Spanish population.

Nicolas R Robles1, Francisco J Felix, Daniel Fernandez-Berges, Jose F Perez-Castán, Maria J Zaro, Luis Lozano, Paula Alvarez-Palacios, Antonio Garcia-Trigo, Veronica Tejero, Yolanda Morcillo, Ana B Hidalgo.   

Abstract

OBJECTIVES: HERMEX is a population-based study which tries to evaluate the relative weight of cardiovascular risk factors in inhabitants of Extremadura, Spain. This report presents the data about chronic kidney disease (CKD) in a Spanish population sample.
METHODS: For an observational cross-sectional population-based study, 3,402 subjects were randomly selected from health care system records. The final sample included 2,813 participants (mean age 51.2 years, 53.5% women). Renal function was estimated from serum creatinine using the 4-variable Modification of Diet in Renal Disease (MDRD-4) Study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. Individual renal risk was calculated using the Kidney Disease Improving Global Outcomes (KDIGO) table.
RESULTS: Using the CKD-EPI formula, 3.6% of participants had a glomerular filtration rate (GFR) <60 ml/min. MDRD-4 gave a result of 4.0%. Prevalence of albuminuria was 5.5%. Taken together, in patients with albuminuria and/or reduced GFR, the prevalence of renal disease was 8.1%. The KDIGO renal risk table suggested that 0.05% of patients were at high or very high risk of CKD progression and 1.6% at medium risk. CKD was more common in those who were obese, hypertensive, dyslipidemic or had diabetes. Multivariate analysis showed an independent negative association of CKD as dependent variable with systolic blood pressure and body mass index, but a positive correlation with diastolic blood pressure and male sex.
CONCLUSIONS: A low frequency of abnormal GFR was detected in a randomly selected sample of the Spanish general population. This finding agreed with the low rates of cardiovascular mortality and morbidity observed in Spain in spite of a high prevalence of classic cardiovascular risk factors.

Entities:  

Mesh:

Year:  2012        PMID: 23100180     DOI: 10.5301/jn.5000221

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  4 in total

1.  A comparison of cystatin C concentrations between patients with chronic interstitial nephritis and glomerular diseases.

Authors:  Nicolas Roberto Robles; Candido Mena; Edgar Chavez; Miguel Angel Bayo; Boris Gonzalez Candia; Antonio Cidoncha; Juan Lopez Gomez; Juan Jose Cubero
Journal:  J Clin Lab Anal       Date:  2017-02-10       Impact factor: 2.352

2.  The H.U.G.E. Formula (Hematocrit, Urea, Sex) for Screening Chronic Kidney Disease (CKD) in an Age-Stratified General Population.

Authors:  N R Robles; F J Felix; L Lozano; I Miranda; D Fernandez-Berges; J F Macías
Journal:  J Nutr Health Aging       Date:  2015-06       Impact factor: 4.075

Review 3.  Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review.

Authors:  Katharina Brück; Kitty J Jager; Evangelia Dounousi; Alexander Kainz; Dorothea Nitsch; Johan Ärnlöv; Dietrich Rothenbacher; Gemma Browne; Vincenzo Capuano; Pietro Manuel Ferraro; Jean Ferrieres; Giovanni Gambaro; Idris Guessous; Stein Hallan; Mika Kastarinen; Gerjan Navis; Alfonso Otero Gonzalez; Luigi Palmieri; Solfrid Romundstad; Belinda Spoto; Benedicte Stengel; Charles Tomson; Giovanni Tripepi; Henry Völzke; Andrzej Wiȩcek; Ron Gansevoort; Ben Schöttker; Christoph Wanner; Jose Vinhas; Carmine Zoccali; Wim Van Biesen; Vianda S Stel
Journal:  Nephrol Dial Transplant       Date:  2015-08       Impact factor: 5.992

Review 4.  Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.

Authors:  Nathan R Hill; Samuel T Fatoba; Jason L Oke; Jennifer A Hirst; Christopher A O'Callaghan; Daniel S Lasserson; F D Richard Hobbs
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.